WO1980000453A1 - Enzymatic processes - Google Patents

Enzymatic processes Download PDF

Info

Publication number
WO1980000453A1
WO1980000453A1 PCT/GB1979/000139 GB7900139W WO8000453A1 WO 1980000453 A1 WO1980000453 A1 WO 1980000453A1 GB 7900139 W GB7900139 W GB 7900139W WO 8000453 A1 WO8000453 A1 WO 8000453A1
Authority
WO
WIPO (PCT)
Prior art keywords
enzyme
process according
reducing equivalents
electrode
working electrode
Prior art date
Application number
PCT/GB1979/000139
Other languages
French (fr)
Inventor
I Higgins
H Hill
Original Assignee
Nat Res Dev
I Higgins
H Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Res Dev, I Higgins, H Hill filed Critical Nat Res Dev
Priority to DE7979900897T priority Critical patent/DE2966707D1/en
Publication of WO1980000453A1 publication Critical patent/WO1980000453A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00Preparation of oxygen-containing organic compounds
    • C12P7/02Preparation of oxygen-containing organic compounds containing a hydroxy group
    • C12P7/04Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M21/00Bioreactors or fermenters specially adapted for specific uses
    • C12M21/18Apparatus specially designed for the use of free, immobilized or carrier-bound enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M35/00Means for application of stress for stimulating the growth of microorganisms or the generation of fermentation or metabolic products; Means for electroporation or cell fusion
    • C12M35/08Chemical, biochemical or biological means, e.g. plasma jet, co-culture
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00Preparation of oxygen-containing organic compounds
    • C12P7/24Preparation of oxygen-containing organic compounds containing a carbonyl group

Definitions

  • This invention relates to enzymatic processes, in particular to processes for the oxidative or reductive transformation of organic compounds utilising redox enzymes.
  • Redox enzymes such as external mono-oxygenases catalyse a wide range of oxidation and reduction reactions in biological systems, many of which are potentially of great industrial importance. In order to accomplish their enzymatic functions, however, these enzymes require a continuing supply of reducing equivalents, normally in the form of electrons, which, in biological systems, are supplied to the enzyme by biologically active electron donor materials, such as NAD and cytochromes. In nature these donor materials undergo continuous regeneration in interactions associated with the main enzyme reaction, but industrial applications of these enzymes would not normally permit this regeneration to take place and thus a continuing supply of fresh donor material would be required to drive the enzyme reaction.
  • electrochemical regeneration of NAD in enzymatically active form has been investigated with a view to coupling this regeneration with enzymatic reactions in which NAD interacts with a substrate material.
  • electrochemical regeneration of the oxidised form of NAD has been coupled with alcohol dehydrogenation catalysed by alcohol dehydrogenase immobilised on alumina (Coughlin et al Biotechnology and Bioengineering (1975) Vol. XVII, pages 515-526) in a reaction in which free NAD + is electrochemically regenerated and acts as a hydrogen acceptor converting the alcohol to an aldehyde.
  • the alcohol dehydrogenase of this reaction acts as a site for interaction of the NAD + and the alcohol, and does not itself undergo chemical change during the reaction to provide an enzymically active reduced enzyme species.
  • Electron donor materials such as NAD and cytochromes are highly costly, complex, unstable chemicals, some comprising protein components and thus their use as reagents in industrial processes is not at present practical.
  • the present invention comprises a process for carrying out an enzymatic reaction which requires a continuing supply of reducing equivalents to regenerate a reduced enzyme species in enzymatically active form, in which the reducing equivalents are derived electrochemically.
  • Suitable enzymes are characteristically those which are capable of accepting electrons to produce a reduced enzyme species which generally corresponds to the enzymatically active form of the enzyme.
  • the enzymes typically comprise at least one electron receptor component which is an integral part of the enzyme molecule or system.
  • theenzyme may comprise a single identifiable molecular species which contains either a metal atom which is directly reduced, or a small molecular prosthetic group permanently bound to the enzyme, such as a flavo protein or pteridine, or a normally free species e.g. NAD, which is bound by the enzyme and whilst bound is reduced and acts as the electron receptor.
  • the enzyme may comprise a multi-protein complex, in which case there is at least one species within the complex, such as ferredoxin, rubredoxin or a cytochrome e.g. cytochrome P450, which acts as an electron receptor and supplies the reducing electrons to the reactive species in the enzyme complex, often by way of a chain of intermediate proteins.
  • a species within the complex such as ferredoxin, rubredoxin or a cytochrome e.g. cytochrome P450, which acts as an electron receptor and supplies the reducing electrons to the reactive species in the enzyme complex, often by way of a chain of intermediate proteins.
  • the enzymes which may be used in the process of the present invention are typically redox enzymes including external mono-oxygenases, oxidoreductases, dehydrogenases, hydrogenases, nitrogenases, dioxygenases and luciferases.
  • redox enzymes including external mono-oxygenases, oxidoreductases, dehydrogenases, hydrogenases, nitrogenases, dioxygenases and luciferases.
  • the enzymatic reactions of the invention are those which involve incorporation of molecular oxygen to provide an enzyme/substrate/molecular oxygen complex during reaction.
  • suitable enzymes and enzymatic reactions utilising these enzymes will be apparent to workers skilled in the art.
  • the processes of the invention are processes for the oxidative or reductive transformation of organic compounds in which the transformation is catalysed by an enzyme and the enzyme requires a continuing supply of reducing equivalents to regenerate a reduced enzyme species in enzymatically active form, and in which the reducing equivalents are derived electrochemically.
  • the organic compounds which may be transformed by the processes of the invention are compounds which characteristically comprise hydrocarbon material and may also comprise functional groups, such as hydroxyl, carbonyl and other groups, and the transformations which may be carried out may be transfor mations of the hydrocarbon material and/or functional groups attached thereto. It will be appreciated that many of such transformations are potentially of great industrial importance.
  • enzymes and enzymatic processes for effecting transformation of organic compounds to which the present invention may be applied include: 1. External Mono-Oxygenases -
  • Microbial higher alkane mono-oxygenases of both of cytochrome P-450 and rubredoxin classes including oxygenases of alkanes e.g. n-octane, alicyclic hydrocarbons, and related systems especially terpenes.
  • Microbial flavin mono-oxygenases such as p-hydroxy- benzoate, salicylate, orcinol and melilotate mono- oxygenases.
  • NADH-linked methane mono-oxygenases for instance the systems isolated from Methylococcus capsulatus or Methylosinus trichosporium which show a very broad substrate specificity, e.g. as described by Higgins et al, Society of General Microbiology Quarterly, 6, 71 (1979) and Biochemical Biophysical Research Communications (1979) (in press), and by
  • Oxidoreductases e.g. ethanol, methanol, lactate, fumarate, succinate oxidoreductases (i.e. including NAD-, flavin- and pteridine-linked enzymes).
  • Dehydrogenases e.g. pyruvate and 2-oxo-glutarate dehydrogenases. 4. Nitrogenase.
  • Dioxygenases that require a reducing agent e.g. bacterial benzene and toluene oxygenases.
  • the electrochemically derived reducing equivalents i.e. electrons may be passed indirectly to the enzyme by means of a suitable carrier.
  • the carrier may comprise a naturally occurring biological carrier such as those biologically active electron donor materials e.g. ferredoxin, pteridine, NAD(P)H, flavins, rubredoxin or free cytochromes, which are associated with the function of enzymes in biological systems.
  • the carrier may comprise an artificial carrier, such as quinone, viologen dye, glutathione or ascorbic acid.
  • the electrochemically derived reducing equivalents are passed directly to the enzyme from the cathode of the electro-chemical system and are used and taken up by the electron receptor component e.g.
  • the choice of electrodes and electrochemical cell used as well as careful control of the electrochemical conditions employed have been found to be of importance.
  • material which is inert to the biologically active material which it is desired to reduce electrochemically is generally used for the working electrode e.g. gold, platinum, carbon or mercury, and the auxiliary electrode, which may be any suitable material, e.g. graphite, is separated from the working electrode, for instance by an electrically conducting membrane.
  • the electro-chemical conditions employed it is of primary importance to ensure that electron transfer to the carrier or enzyme is not rendered ineffective e.g. by the carrier or enzyme undergoing chemical change, or decomposition or by becoming absorbed at the working electrode i.e.
  • cathode This may be achieved by use of a liquid crystal coated, serai-conductor or hanging mercury drop working electrode and/or by use of an electron transfer promoter in the electrolyte.
  • Suitable promoters include 4, 4' -bipyridyl, and 1, 2 - (bis-4,4'-bipyridyl) ethylene and similar conjugated and/or heterocyclic chemicals.
  • the potential of the working electrode at or close to the redox potential of the enzyme or carrier species which it is desired to reduce electrochemically.
  • Such control of the potential of the working electrode advantageously permits se. active reduction of the desired enzyme or carrier species, fcr instance, even when the desired enzyme is present in a complex mixture, such as a crude cell extract.
  • the redox potentials of each enzyme or carrier species are typically distinctive of the species.
  • the redox potential of the mono-cxygenase enzyme system of Methylosinus trichosporium has been found to be approximately -0.1v versus the potential of the normal hydrogen electrode.
  • the desired redox potentials may be determined empirically in each case by methods well known in the electrochemical art.
  • a third electrode is typically included within the electrochemical cell.
  • a reference electrode such as a standard calomel reference electrode, is used, preferably located within the working region of the cell especially in close proximity to the working electrode. Any suitable means may be used to control the potential of the working electrode, such as, for example a potentiostat.
  • the enzyme is introduced into the working compartment of a suitable electrochemical cell, electrochemically derived reducing equivalents are supplied to the enzyme, and substrate is supplied to the system and products recovered as desired.
  • regeneration of the enzyme and transformation of the organic compound substrate material takes place simul taneously, for instance in a homogeneous system.
  • the enzyme may be in purified form, although this is not normally necessary as choice of preferred operating potential advantageously permits selective electrochemical regeneration of the enzyme e.g. as a component of a crude cell extract.
  • the enzyme may be present in the electrolyte in the free state, or, in preferred embodiments for use in industrial applications, the enzyme may be immobilised, for instance, on or with a suitable solid phase material e.g. polysaccharide gel beads or absorbed on carbon particles. Also immobilised enzyme may be used advantageously in flow-through reactor systems, in which substrate may be flowed through the reactor and products recovered down stream of the reactor.
  • the required reducing equivalents may be supplied electrochemically from molecular hydrogen.
  • molecular hydrogen is passed into a secondary solution in which the reaction H 2 ⁇ 2H + + 2e occurs e.g. a solution containing a hydrogenase.
  • This solution contains an electrode e.g. a platinised platinum electrode, which is electrically connected to a second electrode immersed in a primary solution containing the enzymatic reaction system.
  • Electrons supplied by the reaction of molecular hydrogen in the secondary solution are passed to an enzyme in the primary solution enabling the enzyme to interact with substrate e.g. methane and molecular oxygen.
  • the electrochemical/enzymatic oxidation of methane to methanol is carried out in an electrochemical cell using a crude enzyme extract of Methylosinus trichosporium.
  • the electrochemical cell used consists of two compartments, a working compartment and an auxiliary compartment, separated from one another by a Vycor (Corning Inc.) glass membrane.
  • the working compartment contains a gold foil working electrode of surface area approximately 9 cm 2 , and in close proximity a standard calomel reference electrode the tip of which is within 1 mm of the gold electrode.
  • a graphite rod anode is situated in the auxiliary compartment, and both compartments contain potassium phosphate as electrolyte.
  • the potential of the working electrode relative to the standard calomel electrode is controlled by a Princeton Applied Research potentiostat model 173.
  • a crude cell-free extract of methane-grown Methylosinus trichosporium is prepared as described by Tonge, Harrison and Higgins (Biochemical Journal, 161, (1977), 333-344).
  • 9.5 ml of the extract containing 85 mg. of protein is introduced to the working compartment of the electrochemical cell together with a few crystals of cupric chloride and 4,4'-bipyridyl (5mM).
  • the potentiostat is set to maintain the potential of the working electrode relative to the standard calomel electrode at -0.1V vs. the normal hydrogen electrode.
  • the contents of the electro-chemical cell are incubated at room temperature, and magnetically stirred, whilst methane/air mixture (1:1v/v) is bubbled through the working compartment.
  • the electric current and gas flow are switched off and the contents of the working compartment are assayed for methanol produced from the methane.
  • concentration of methanol in the mixture is found to be 60 ⁇ M. It was also found that the oxidation of methane to methanol was inhibited by carbon monoxide and cyanide, both of which are known inhibitors of the methane mono-oxygenase of Methylosinus trichosporium.
  • the methane mono-oxygenase system of this organism is known to have a very broad substrate specificity, as described by
  • Camphor is oxidised to 5-exo-hydroxy-camphor using the camphor mono-oxygenase complex of Pseudomonas putida, the reducing equivalents required to drive the reaction being supplied electrochemically directly to the enzyme.
  • the enzyme complex which consists of cytochrome P 450 cam putidaredoxin and putidaredoxin reductase, is isolated from Pseudomonas putida strain PpG 786 using the procedures of Gunsalus and Wagner (Methods in Enzymology, 52, 166-188, 1978) except that bacterial disruption is modified by use of the lysozyme-EDTA method of O'Keefe et al (Methods in Enzymology, 52, 151-157, 1978).
  • the reaction solution contained in the working compartment of the cell contains putidaredoxin (10 mg) , reductase (2 mg) and cytochrome P-450 (24 nanomoles) in 5-4 ml of Tris (0.05 M) , K Cl (0.1M) buffer at pH 7.4, and is saturated with camphor.
  • the reaction is carried out at 28oC with a preferred applied potential of -800 mV vs S.C.E. No 5-exo-hydroxycamphor is detected at zero time but the concentration of this compound steadily increases with time, the presence of this product in the reaction mixture being determined by ether extraction of samples followed by analysis by gas liquid chromatography.
  • the yield of hydroxy camphor obtained is of the order of 80 n mol/mg of protein/min.
  • Luciferase a flavoprotein enzyme which catalyses the reaction NADH + FMN + aldehyde + O 2 ⁇ light + products, is investigated in a system in which the reducing equivalents required for the enzyme reaction are supplied electrochemically directly to the enzyme.
  • the luciferase used is obtained from Vihrio Fisheri as supplied by Sigma Chemical Co., and identified as type II Cat. No. 2379.
  • the luciferase reactions are carried out in an electrochemical cell sited adjacent to a photomultiplier tube of an Aminco photometer which is used to measure the light emitted during the reaction.
  • the electrochemical cell used comprises two compartments, a working compartment containing the reaction mixture and a gold gauze working electrode, and an auxiliary compartment separated from the working compartment by dialysis tubing and containing a platinum wire counter electrode.
  • the reaction mixture contains luciferase (7 mg), decyl aldehyde (0.05 ml) and phosphate buffer (1.5 ml at pH 7.0) being made up to a total volume of 8 ml.
  • a standard calomel reference electrode is sited in the working compartment close to the working electrode and all three electrodes are appropriately connected to a Chemical Electronics potentiostat.
  • the applied potential is arranged such that the working electrode is initially set at a potential of 0.0 V vs the S.C.E., after which the potential is gradually made more negative.
  • the potential reaches -700 mV the photometer indicates that light is being emitted by the reaction mixture, and the amount of light emitted increases as the potential is made more negative.
  • the most negative potential used being -900 mV. As the potential is made more positive the amount of light emitted decreases.
  • the potential is cycled several times between 0V and -900 mV, and each time light is emitted at potentials more negative than 700 mV thereby showing that, the catalysis by the enzyme depended on the transfer of electrons from the electrode to the enzyme.
  • the reducing equivalents are supplied electrochemically from molecular hydrogen in a heterogeneous system.
  • the system used comprises two compartments separated by a glass frit membrane, one compartment containing a Johnson Matthey platinum fuel cell electrode (5 mm x 15 mm) maintained in phosphate buffer solution (pH 7) containing sodium perchlorate (0.01M).
  • the other compartment of the system contains a gold net working electrode ( 10 mm x 5 mm) immersed in the same solution, though containing in addition cytochrome c (5 mg/ml) and 4,4-bipyridyl (10 mM) .
  • the electrodes in the two compartments are provided with means for electrical connection between them, and the open circuit potential is found to be 630 mV, that which is expected from the reduction potential of cytochrome c.

Abstract

There are provided processes for carrying out enzymatic reactions, especially processes for the oxidative or reductive transformation of organic compounds catalysed by enzymes, in which the enzymes require a continuing supply of reducing equivalents to regenerate reduced enzyme species in enzymatically active form, and in which the reducing equivalents are derived electrochemically, including electrochemically from molecular hydrogen, the reducing equivalents preferably being passed directly to the enzyme from the cathode of an electrochemical system.

Description

ENZYMATIC PROCESSES This invention relates to enzymatic processes, in particular to processes for the oxidative or reductive transformation of organic compounds utilising redox enzymes.
Redox enzymes such as external mono-oxygenases catalyse a wide range of oxidation and reduction reactions in biological systems, many of which are potentially of great industrial importance. In order to accomplish their enzymatic functions, however, these enzymes require a continuing supply of reducing equivalents, normally in the form of electrons, which, in biological systems, are supplied to the enzyme by biologically active electron donor materials, such as NAD and cytochromes. In nature these donor materials undergo continuous regeneration in interactions associated with the main enzyme reaction, but industrial applications of these enzymes would not normally permit this regeneration to take place and thus a continuing supply of fresh donor material would be required to drive the enzyme reaction.
In recent years the electrochemical regeneration of NAD in enzymatically active form has been investigated with a view to coupling this regeneration with enzymatic reactions in which NAD interacts with a substrate material. For example, electrochemical regeneration of the oxidised form of NAD has been coupled with alcohol dehydrogenation catalysed by alcohol dehydrogenase immobilised on alumina (Coughlin et al Biotechnology and Bioengineering (1975) Vol. XVII, pages 515-526) in a reaction in which free NAD+ is electrochemically regenerated and acts as a hydrogen acceptor converting the alcohol to an aldehyde. The alcohol dehydrogenase of this reaction acts as a site for interaction of the NAD+ and the alcohol, and does not itself undergo chemical change during the reaction to provide an enzymically active reduced enzyme species.
Additionally, however, it is highly likely that NAD will be continually lost by decomposition or otherwise and it will be necessary to "top up" the system with fresh NAD from time to time. Electron donor materials, such as NAD and cytochromes are highly costly, complex, unstable chemicals, some comprising protein components and thus their use as reagents in industrial processes is not at present practical.
It has now been discovered that enzyme reactions which proceed by way of a reduced enzyme species may be carried out without need for biochemical regeneration of electron donor materials and preferably also without the need for a continued supply of fresh donor material either to replace spent material or, in a particularly preferred embodiment, even to "top up" the system.
Accordingly the present invention comprises a process for carrying out an enzymatic reaction which requires a continuing supply of reducing equivalents to regenerate a reduced enzyme species in enzymatically active form, in which the reducing equivalents are derived electrochemically.
Suitable enzymes are characteristically those which are capable of accepting electrons to produce a reduced enzyme species which generally corresponds to the enzymatically active form of the enzyme. Thus the enzymes typically comprise at least one electron receptor component which is an integral part of the enzyme molecule or system. For instance, theenzyme may comprise a single identifiable molecular species which contains either a metal atom which is directly reduced, or a small molecular prosthetic group permanently bound to the enzyme, such as a flavo protein or pteridine, or a normally free species e.g. NAD, which is bound by the enzyme and whilst bound is reduced and acts as the electron receptor. Also, however, the enzyme may comprise a multi-protein complex, in which case there is at least one species within the complex, such as ferredoxin, rubredoxin or a cytochrome e.g. cytochrome P450, which acts as an electron receptor and supplies the reducing electrons to the reactive species in the enzyme complex, often by way of a chain of intermediate proteins.
The enzymes which may be used in the process of the present invention are typically redox enzymes including external mono-oxygenases, oxidoreductases, dehydrogenases, hydrogenases, nitrogenases, dioxygenases and luciferases. Often the enzymatic reactions of the invention are those which involve incorporation of molecular oxygen to provide an enzyme/substrate/molecular oxygen complex during reaction. Specific examples of suitable enzymes and enzymatic reactions utilising these enzymes will be apparent to workers skilled in the art. Typically, however, the processes of the invention are processes for the oxidative or reductive transformation of organic compounds in which the transformation is catalysed by an enzyme and the enzyme requires a continuing supply of reducing equivalents to regenerate a reduced enzyme species in enzymatically active form, and in which the reducing equivalents are derived electrochemically. The organic compounds which may be transformed by the processes of the invention are compounds which characteristically comprise hydrocarbon material and may also comprise functional groups, such as hydroxyl, carbonyl and other groups, and the transformations which may be carried out may be transfor mations of the hydrocarbon material and/or functional groups attached thereto. It will be appreciated that many of such transformations are potentially of great industrial importance. For example, enzymes and enzymatic processes for effecting transformation of organic compounds to which the present invention may be applied include: 1. External Mono-Oxygenases -
(i) Microbial higher alkane mono-oxygenases of both of cytochrome P-450 and rubredoxin classes including oxygenases of alkanes e.g. n-octane, alicyclic hydrocarbons, and related systems especially terpenes. (ii) Microsomal cytochrome P450 enzymes from eukaryotic organisms, including systems involved in prostaglandin synthesis, ω-hydroxylation of fatty acids, fatty acid desaturation, cyclization of squalene, steroid inter-conversions and bile acid metabolism. (iii) Microbial flavin mono-oxygenases such as
Figure imgf000007_0001
p-hydroxy- benzoate, salicylate, orcinol and melilotate mono- oxygenases. (iv) NADH-linked methane mono-oxygenases, for instance the systems isolated from Methylococcus capsulatus or Methylosinus trichosporium which show a very broad substrate specificity, e.g. as described by Higgins et al, Society of General Microbiology Quarterly, 6, 71 (1979) and Biochemical Biophysical Research Communications (1979) (in press), and by
Stirling et al, Biochera. J. , 177, (1979) 361-364. (v) Mono-oxygenases which catalyse ring-insertion reactions e.g. cyclohexanone mono-oxygenase. (vi) O-Demethylases. (vii) Phenylalanine, tyrosine and tryptophan hydroxylases.
2. Oxidoreductases e.g. ethanol, methanol, lactate, fumarate, succinate oxidoreductases (i.e. including NAD-, flavin- and pteridine-linked enzymes).
3. Dehydrogenases e.g. pyruvate and 2-oxo-glutarate dehydrogenases. 4. Nitrogenase.
5. Dioxygenases that require a reducing agent e.g. bacterial benzene and toluene oxygenases.
6. Luciferases that require a reducing agent. 7. Hydrogenases.
The electrochemically derived reducing equivalents i.e. electrons, may be passed indirectly to the enzyme by means of a suitable carrier. The carrier may comprise a naturally occurring biological carrier such as those biologically active electron donor materials e.g. ferredoxin, pteridine, NAD(P)H, flavins, rubredoxin or free cytochromes, which are associated with the function of enzymes in biological systems. Alternatively the carrier may comprise an artificial carrier, such as quinone, viologen dye, glutathione or ascorbic acid. Preferably, however, the electrochemically derived reducing equivalents are passed directly to the enzyme from the cathode of the electro-chemical system and are used and taken up by the electron receptor component e.g. flavoprotein or cytochrome component of the enzyme. Such direct electrochemical reduction of the enzyme advantageously avoids the use of a carrier material which may comprise an undesirably expensive and chemically unstable material which requires periodic replacement because of loss due to decomposition or otherwise. Thus in the method of the present invention a carrier or preferably the enzyme itself is continuously reduced electrochemically to drive the enzymatic reaction.
In order to successfully continue transfer of electrons to the carrier or the enzyme, the choice of electrodes and electrochemical cell used as well as careful control of the electrochemical conditions employed have been found to be of importance. For example, material which is inert to the biologically active material which it is desired to reduce electrochemically is generally used for the working electrode e.g. gold, platinum, carbon or mercury, and the auxiliary electrode, which may be any suitable material, e.g. graphite, is separated from the working electrode, for instance by an electrically conducting membrane. As regards the electro-chemical conditions employed, it is of primary importance to ensure that electron transfer to the carrier or enzyme is not rendered ineffective e.g. by the carrier or enzyme undergoing chemical change, or decomposition or by becoming absorbed at the working electrode i.e. cathode. This may be achieved by use of a liquid crystal coated, serai-conductor or hanging mercury drop working electrode and/or by use of an electron transfer promoter in the electrolyte. Suitable promoters include 4, 4' -bipyridyl, and 1, 2 - (bis-4,4'-bipyridyl) ethylene and similar conjugated and/or heterocyclic chemicals.
Furthermore, it has been found to be desirable to control the potential of the working electrode at or close to the redox potential of the enzyme or carrier species which it is desired to reduce electrochemically. Such control of the potential of the working electrode advantageously permits se. active reduction of the desired enzyme or carrier species, fcr instance, even when the desired enzyme is present in a complex mixture, such as a crude cell extract. The redox potentials of each enzyme or carrier species are typically distinctive of the species. For example, the redox potential of the mono-cxygenase enzyme system of Methylosinus trichosporium has been found to be approximately -0.1v versus the potential of the normal hydrogen electrode. The desired redox potentials may be determined empirically in each case by methods well known in the electrochemical art.
In order to facilitate control of the working electrode at the desired redox potential, a third electrode is typically included within the electrochemical cell. For instance, a reference electrode, such as a standard calomel reference electrode, is used, preferably located within the working region of the cell especially in close proximity to the working electrode. Any suitable means may be used to control the potential of the working electrode, such as, for example a potentiostat.
In the processes of the invention the enzyme is introduced into the working compartment of a suitable electrochemical cell, electrochemically derived reducing equivalents are supplied to the enzyme, and substrate is supplied to the system and products recovered as desired. Generally regeneration of the enzyme and transformation of the organic compound substrate material takes place simul taneously, for instance in a homogeneous system. The enzyme may be in purified form, although this is not normally necessary as choice of preferred operating potential advantageously permits selective electrochemical regeneration of the enzyme e.g. as a component of a crude cell extract. The enzyme may be present in the electrolyte in the free state, or, in preferred embodiments for use in industrial applications, the enzyme may be immobilised, for instance, on or with a suitable solid phase material e.g. polysaccharide gel beads or absorbed on carbon particles. Also immobilised enzyme may be used advantageously in flow-through reactor systems, in which substrate may be flowed through the reactor and products recovered down stream of the reactor.
As an alternative to the supply of reducing equivalents by means of a conventional electrochemical cell, the required reducing equivalents may be supplied electrochemically from molecular hydrogen. For example, in a heterogeneous system molecular hydrogen is passed into a secondary solution in which the reaction H2→2H+ + 2e occurs e.g. a solution containing a hydrogenase. This solution contains an electrode e.g. a platinised platinum electrode, which is electrically connected to a second electrode immersed in a primary solution containing the enzymatic reaction system. Electrons supplied by the reaction of molecular hydrogen in the secondary solution are passed to an enzyme in the primary solution enabling the enzyme to interact with substrate e.g. methane and molecular oxygen. The invention is further described by way of illustration only in the following examples. Example 1
The electrochemical/enzymatic oxidation of methane to methanol is carried out in an electrochemical cell using a crude enzyme extract of Methylosinus trichosporium.
The electrochemical cell used consists of two compartments, a working compartment and an auxiliary compartment, separated from one another by a Vycor (Corning Inc.) glass membrane. The working compartment contains a gold foil working electrode of surface area approximately 9 cm2, and in close proximity a standard calomel reference electrode the tip of which is within 1 mm of the gold electrode. A graphite rod anode is situated in the auxiliary compartment, and both compartments contain potassium phosphate as electrolyte. The potential of the working electrode relative to the standard calomel electrode is controlled by a Princeton Applied Research potentiostat model 173.
A crude cell-free extract of methane-grown Methylosinus trichosporium is prepared as described by Tonge, Harrison and Higgins (Biochemical Journal, 161, (1977), 333-344). 9.5 ml of the extract containing 85 mg. of protein is introduced to the working compartment of the electrochemical cell together with a few crystals of cupric chloride and 4,4'-bipyridyl (5mM). The potentiostat is set to maintain the potential of the working electrode relative to the standard calomel electrode at -0.1V vs. the normal hydrogen electrode. The contents of the electro-chemical cell are incubated at room temperature, and magnetically stirred, whilst methane/air mixture (1:1v/v) is bubbled through the working compartment. After about 90 minutes, at which point about 0.1 coulomb of electricity has passed through the cell, the electric current and gas flow are switched off and the contents of the working compartment are assayed for methanol produced from the methane. The concentration of methanol in the mixture is found to be 60μM. It was also found that the oxidation of methane to methanol was inhibited by carbon monoxide and cyanide, both of which are known inhibitors of the methane mono-oxygenase of Methylosinus trichosporium.
The methane mono-oxygenase system of this organism is known to have a very broad substrate specificity, as described by
Higgins et_ al (Society of General Microbiology Quarterly, 6, 71, 1979), being capable of oxidising higher alkanes, alkenes and even cyclic organic compounds. It is to be expected, therefore, that such other compounds will be oxidised electroenzymologically substantially as described above. Also the mono-oxygenase enzyme system of Methylosinus trichosporium is broadly similar to the enzyme systems of other methane mono-oxygenase organisms, such as Methylococcus capsulatus, and thus enzyme systems from methane mono-oxygenase organisms in general may be utilised in similar electroenzyrrtolσgical oxidations. Example 2
Camphor is oxidised to 5-exo-hydroxy-camphor using the camphor mono-oxygenase complex of Pseudomonas putida, the reducing equivalents required to drive the reaction being supplied electrochemically directly to the enzyme. The enzyme complex which consists of cytochrome P450 cam putidaredoxin and putidaredoxin reductase, is isolated from Pseudomonas putida strain PpG 786 using the procedures of Gunsalus and Wagner (Methods in Enzymology, 52, 166-188, 1978) except that bacterial disruption is modified by use of the lysozyme-EDTA method of O'Keefe et al (Methods in Enzymology, 52, 151-157, 1978). Investigation of the DC and AC voltammetry of the complex, coupled with spectroelectrochemical measurements indicate that the complex is reduced, in the presence of camphor, at a gold electrode at - 700 mV vs S.C.E. The oxidation of camphor is carried out in a two compartment electrochemical cell fitted with a gold gauze working electrode, a platinum wire counter electrode, and a standard calomel reference electrode mounted in the working compartment of the cell in close proximity to the working electrode. The counter electrode is separated from the working electrode compartment by dialysis tubing. The reaction solution contained in the working compartment of the cell contains putidaredoxin (10 mg) , reductase (2 mg) and cytochrome P-450 (24 nanomoles) in 5-4 ml of Tris (0.05 M) , K Cl (0.1M) buffer at pH 7.4, and is saturated with camphor. The reaction is carried out at 28ºC with a preferred applied potential of -800 mV vs S.C.E. No 5-exo-hydroxycamphor is detected at zero time but the concentration of this compound steadily increases with time, the presence of this product in the reaction mixture being determined by ether extraction of samples followed by analysis by gas liquid chromatography. Using partially purified enzyme (~30% pure) the yield of hydroxy camphor obtained is of the order of 80 n mol/mg of protein/min.
Comparison of the results obtained with the same reaction driven by the "natural" electron donor, NADH, indicate that in the electroenzymological application the rate of production of the product proceeds at a rate of about one third of that obtained with the "natural" system. It is envisaged, however, that modification of the cell design to optimise the mass transport should give rise to a more comparable rate of product formatIon.
An experiment carried out at a working electrode potential of -600 mV vs S.C.E. gives a much reduced rate of product formation, approximately one fifth of that observed in the earlier experiment, indicating that reduction of the enzyme at the electrode surface is the rate determining step. A further experiment carried out in the absence of the enzyme complex gives no product formation. Example 3
Luciferase, a flavoprotein enzyme which catalyses the reaction NADH + FMN + aldehyde + O2 → light + products, is investigated in a system in which the reducing equivalents required for the enzyme reaction are supplied electrochemically directly to the enzyme. The luciferase used is obtained from Vihrio Fisheri as supplied by Sigma Chemical Co., and identified as type II Cat. No. 2379.
The luciferase reactions are carried out in an electrochemical cell sited adjacent to a photomultiplier tube of an Aminco photometer which is used to measure the light emitted during the reaction. The electrochemical cell used comprises two compartments, a working compartment containing the reaction mixture and a gold gauze working electrode, and an auxiliary compartment separated from the working compartment by dialysis tubing and containing a platinum wire counter electrode. The reaction mixture contains luciferase (7 mg), decyl aldehyde (0.05 ml) and phosphate buffer (1.5 ml at pH 7.0) being made up to a total volume of 8 ml. A standard calomel reference electrode is sited in the working compartment close to the working electrode and all three electrodes are appropriately connected to a Chemical Electronics potentiostat. The applied potential is arranged such that the working electrode is initially set at a potential of 0.0 V vs the S.C.E., after which the potential is gradually made more negative. When the potential reaches -700 mV the photometer indicates that light is being emitted by the reaction mixture, and the amount of light emitted increases as the potential is made more negative. The most negative potential used being -900 mV. As the potential is made more positive the amount of light emitted decreases. The potential is cycled several times between 0V and -900 mV, and each time light is emitted at potentials more negative than 700 mV thereby showing that, the catalysis by the enzyme depended on the transfer of electrons from the electrode to the enzyme.
Example 4
As an alternative to the supply of reducing equivalents required to drive the enzyme reaction from a conventional electrochemical cell, the reducing equivalents are supplied electrochemically from molecular hydrogen in a heterogeneous system.
The system used comprises two compartments separated by a glass frit membrane, one compartment containing a Johnson Matthey platinum fuel cell electrode (5 mm x 15 mm) maintained in phosphate buffer solution (pH 7) containing sodium perchlorate (0.01M). The other compartment of the system contains a gold net working electrode ( 10 mm x 5 mm) immersed in the same solution, though containing in addition cytochrome c (5 mg/ml) and 4,4-bipyridyl (10 mM) . The electrodes in the two compartments are provided with means for electrical connection between them, and the open circuit potential is found to be 630 mV, that which is expected from the reduction potential of cytochrome c. This potential is reversed by passing hydrogen gas into the platinum electrode compartment where the hydrogen relinquishes electrons to the platinum electrode which are then passed on to the cytochrome c via the gold net electrode, the hydrogen combining with oxygen to give water. The reduced form of cytochrome c in the gold electrode compartment is then able to interact with cytochrome oxidase and molecule oxygen to drive the oxidation reactions of this latter enzyme e.g. oxidation of methane to methanol. Example 5
The electrochemical reduction of various biologically active electron donor materials, enzyme complexes and components thereof is carried out in a two compartment cell fitted with a platinum counter electrode as described in previous examples. The results obtained are given in the table below indicating the proteins which are electrochemically reduced, their sources, the working electrodes used in each case, their oxidation/reduction potentials (vs the NHE) and comments on the reversibility of the reductions. These protein materials provide biologically active carrier materials for transferring reducing equivalents to enzymes.
Figure imgf000018_0001
Figure imgf000018_0002

Claims

1. A process for carrying out an enzymatic reaction which requires a continuing supply of reducing equivalents to regenerate a reduced enzyme species in enzymatically active form, in which the reducing equivalents are derived electro-chemically.
2. A process for the oxidative or reductive transformation of an organic compound, in which the transformation is catalysed by an enzyme and the enzyme requires a continuing supply of reducing equivalents to regenerate a reduced enzyme species in enzymatically active form, and in which the reducing equivalents are derived electrochemically.
3. A process according to Claim 1 or 2, in which the enzyme comprises an external mono-oxygenase, an oxidore-ductase, a dehydrogenase, a nitrogenase, a dioxygenase, a luciferase or a hydrogenase.
4. A process according to any of the prededing claims, in which the electrochemically derived reducing equivalents are passed directly to the enzyme from the cathode of an electrochemical system and are used and taken up by an electron receptor component of the enzyme.
5. A process according to any of the preceding Claims, in which the working electrode of the electrochemical system comprises a material which is inert to the biologically active material which it is desired to regenerate electro-chemically and the auxiliary electrode is separated from the working electrode.
6. A process according to any of the preceding Claims, in which the working electrode comprises a liquid crystal coated, serai-conductor or hanging mercury drop electrode.
7. A process according to any of the preceding Claims, in which the electrolyte contains an electron transfer promoter.
8. A process according to any of the preceding Claims, in which the potential of the working electrode is controlled at or close to the redox potential of the enzyme or carrier species which it is desired to reduce.
9. A process according to Claim 8, in which control of the potential of the working electrode is facilitated by use of a reference electrode located within the working region of the electrochemical cell.
10. A process according to any of the preceding Claims, in which the enzyme is present as a component of a crude cell extract.
11. A process according to any of the preceding Claims, in which the required reducing equivalents are supplied electrochemically from molecular hydrogen.
12. A process according to any of the preceding Claims, in which a hydrocarbon material is oxidised to an alcohol using a mono-oxygenase enzyme system derived from methane oxidising bacteria e.g. Methylosinus trichosporium.
13. A process according to any of the preceding Claims, in which camphor is oxidised to hydroxy camphor using an enzyme system derived from Pseudomonas putida.
PCT/GB1979/000139 1978-08-15 1979-08-10 Enzymatic processes WO1980000453A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE7979900897T DE2966707D1 (en) 1978-08-15 1979-08-10 Enzymatic processes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB7803338 1978-08-15
GB7833388 1978-08-15

Publications (1)

Publication Number Publication Date
WO1980000453A1 true WO1980000453A1 (en) 1980-03-20

Family

ID=10499064

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1979/000139 WO1980000453A1 (en) 1978-08-15 1979-08-10 Enzymatic processes

Country Status (6)

Country Link
US (1) US4318784A (en)
EP (1) EP0020355B1 (en)
JP (1) JPS55500431A (en)
DE (1) DE2966707D1 (en)
IT (1) IT1165700B (en)
WO (1) WO1980000453A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981000725A1 (en) * 1979-09-14 1981-03-19 Charles Hospital Dev Method of determining a substrate in a sample
EP0030195A1 (en) * 1979-12-03 1981-06-10 Societe D'etudes De Techniques Et De Realisations Industrielles Et Commerciales (Setric) Method of measuring the concentration of an oxidisable or reducible substrate in solution by means of an oxido-reductase enzyme, and device for carrying out such a method
WO1982004113A1 (en) * 1981-05-14 1982-11-25 Kylmaenen Pasi Feeding means for feeding solid fuel from a storage silo or equivalent into a solid fuel heating boiler
EP0068664A1 (en) * 1981-06-12 1983-01-05 Ajinomoto Co., Inc. A heme protein immobilized electrode
EP0099517A2 (en) * 1982-07-17 1984-02-01 BASF Aktiengesellschaft Process for carrying out electromicrobial reductions
EP0125867A2 (en) * 1983-05-05 1984-11-21 MediSense, Inc. Assay systems using enzymes requiring NAD(P) as cofactor
WO1988008029A1 (en) * 1987-04-17 1988-10-20 Centre National De La Recherche Scientifique (Cnrs Electroenzymatic method for producing compounds having a controlled enantiomeric purity
EP0076266B1 (en) * 1981-04-08 1988-11-09 GORTON, Lo Electrode for the electrochemical regeneration of co-enzyme, a method of making said electrode, and the use thereof
US6126795A (en) * 1996-11-27 2000-10-03 The United States Of America As Represented By The Secretary Of Commerce Electroenzymatic reactor and method for enzymatic catalysis
WO2011053478A1 (en) * 2009-10-26 2011-05-05 Saudi Arabian Oil Company Visible light-enhanced enzymatic promotion of hydrocarbon reactions

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3221339A1 (en) * 1982-06-05 1983-12-08 Basf Ag, 6700 Ludwigshafen METHOD FOR THE ELECTROCHEMICAL HYDRATION OF NICOTINAMIDADENINE-DINUCLEOTIDE
GB8500729D0 (en) * 1985-01-11 1985-02-13 Hill H A O Surface-modified electrode
US5538867A (en) * 1988-09-13 1996-07-23 Elf Aquitaine Process for the electrochemical regeneration of pyridine cofactors
US5190870A (en) * 1989-05-16 1993-03-02 Amoco Corporation Method for oxidizing hydrocarbons with a hydroxylase from a methane monooxygenase
US5192672A (en) * 1989-05-16 1993-03-09 Amoco Corporation Method for oxidizing hydrocarbons with a hydroxylase from a methane monooxygenase
US5258627A (en) * 1991-12-04 1993-11-02 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Semiconductor structure using protein as its active element
EP0958495B1 (en) * 1997-02-06 2002-11-13 Therasense, Inc. Small volume in vitro analyte sensor
US9066695B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6175752B1 (en) 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
US6949816B2 (en) 2003-04-21 2005-09-27 Motorola, Inc. Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same
US8688188B2 (en) 1998-04-30 2014-04-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8465425B2 (en) 1998-04-30 2013-06-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8346337B2 (en) 1998-04-30 2013-01-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8974386B2 (en) 1998-04-30 2015-03-10 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8480580B2 (en) 1998-04-30 2013-07-09 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6500571B2 (en) 1998-08-19 2002-12-31 Powerzyme, Inc. Enzymatic fuel cell
US6251260B1 (en) 1998-08-24 2001-06-26 Therasense, Inc. Potentiometric sensors for analytic determination
US6338790B1 (en) 1998-10-08 2002-01-15 Therasense, Inc. Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator
US6591125B1 (en) 2000-06-27 2003-07-08 Therasense, Inc. Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator
GB9821932D0 (en) * 1998-10-09 1998-12-02 Univ Leicester Cytochrome P450 electrochemical system
AU5747100A (en) 1999-06-18 2001-01-09 Therasense, Inc. Mass transport limited in vivo analyte sensor
US20060091006A1 (en) * 1999-11-04 2006-05-04 Yi Wang Analyte sensor with insertion monitor, and methods
US6616819B1 (en) * 1999-11-04 2003-09-09 Therasense, Inc. Small volume in vitro analyte sensor and methods
US7182853B2 (en) * 2000-09-22 2007-02-27 University Of Dayton Redox control/monitoring platform for high throughput screening/drug discovery applications
US6560471B1 (en) 2001-01-02 2003-05-06 Therasense, Inc. Analyte monitoring device and methods of use
US7041468B2 (en) 2001-04-02 2006-05-09 Therasense, Inc. Blood glucose tracking apparatus and methods
US20050176121A1 (en) * 2001-09-06 2005-08-11 Ryo Takeshita Method for producing alcohol by using microorganism
US6747066B2 (en) 2002-01-31 2004-06-08 Conocophillips Company Selective removal of oxygen from syngas
EP1375671A1 (en) * 2002-06-28 2004-01-02 Eidgenössische Technische Hochschule Zürich Selective functionalization of hydrocarbons with isolated oxygenases and mediator-based regeneration
WO2004061420A2 (en) 2002-12-31 2004-07-22 Therasense, Inc. Continuous glucose monitoring system and methods of use
US7587287B2 (en) 2003-04-04 2009-09-08 Abbott Diabetes Care Inc. Method and system for transferring analyte test data
US8066639B2 (en) * 2003-06-10 2011-11-29 Abbott Diabetes Care Inc. Glucose measuring device for use in personal area network
US7045554B2 (en) * 2003-09-03 2006-05-16 Conocophillips Company Method for improved Fischer-Tropsch catalyst stability and higher stable syngas conversion
US7306641B2 (en) * 2003-09-12 2007-12-11 Hewlett-Packard Development Company, L.P. Integral fuel cartridge and filter
EP1718198A4 (en) 2004-02-17 2008-06-04 Therasense Inc Method and system for providing data communication in continuous glucose monitoring and management system
EP1595956A1 (en) * 2004-05-13 2005-11-16 Basf Aktiengesellschaft Process for an enzymatic oxygenation by direct electrochemical regeneration of the FAD-dependent monooxygenase
EP1756557B1 (en) 2004-05-21 2017-03-15 Agamatrix, Inc. Method of making an electrochemical cell
US8112240B2 (en) 2005-04-29 2012-02-07 Abbott Diabetes Care Inc. Method and apparatus for providing leak detection in data monitoring and management systems
US20090281480A1 (en) * 2005-07-05 2009-11-12 David Orlebeke Oxygenation of aqueous systems
US7766829B2 (en) 2005-11-04 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
US7885698B2 (en) 2006-02-28 2011-02-08 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
US8226891B2 (en) 2006-03-31 2012-07-24 Abbott Diabetes Care Inc. Analyte monitoring devices and methods therefor
US7620438B2 (en) 2006-03-31 2009-11-17 Abbott Diabetes Care Inc. Method and system for powering an electronic device
WO2007143225A2 (en) 2006-06-07 2007-12-13 Abbott Diabetes Care, Inc. Analyte monitoring system and method
US8930203B2 (en) 2007-02-18 2015-01-06 Abbott Diabetes Care Inc. Multi-function analyte test device and methods therefor
US8732188B2 (en) 2007-02-18 2014-05-20 Abbott Diabetes Care Inc. Method and system for providing contextual based medication dosage determination
US8123686B2 (en) 2007-03-01 2012-02-28 Abbott Diabetes Care Inc. Method and apparatus for providing rolling data in communication systems
US8461985B2 (en) 2007-05-08 2013-06-11 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8665091B2 (en) 2007-05-08 2014-03-04 Abbott Diabetes Care Inc. Method and device for determining elapsed sensor life
US7928850B2 (en) 2007-05-08 2011-04-19 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8456301B2 (en) 2007-05-08 2013-06-04 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8103456B2 (en) 2009-01-29 2012-01-24 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
US20100213057A1 (en) * 2009-02-26 2010-08-26 Benjamin Feldman Self-Powered Analyte Sensor
WO2010127050A1 (en) 2009-04-28 2010-11-04 Abbott Diabetes Care Inc. Error detection in critical repeating data in a wireless sensor system
US9184490B2 (en) 2009-05-29 2015-11-10 Abbott Diabetes Care Inc. Medical device antenna systems having external antenna configurations
US9314195B2 (en) 2009-08-31 2016-04-19 Abbott Diabetes Care Inc. Analyte signal processing device and methods
WO2011026148A1 (en) 2009-08-31 2011-03-03 Abbott Diabetes Care Inc. Analyte monitoring system and methods for managing power and noise
WO2011041469A1 (en) 2009-09-29 2011-04-07 Abbott Diabetes Care Inc. Method and apparatus for providing notification function in analyte monitoring systems
EP2775918B1 (en) 2011-11-07 2020-02-12 Abbott Diabetes Care Inc. Analyte monitoring device and methods
US9968306B2 (en) 2012-09-17 2018-05-15 Abbott Diabetes Care Inc. Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3919052A (en) * 1973-01-10 1975-11-11 Battelle Memorial Institute Method and apparatus for continuously controlling an enzymatic reaction
DD126807A1 (en) * 1976-07-28 1977-08-10

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3919052A (en) * 1973-01-10 1975-11-11 Battelle Memorial Institute Method and apparatus for continuously controlling an enzymatic reaction
DD126807A1 (en) * 1976-07-28 1977-08-10

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Vol. 83, No. 23, issued December 8, 1975 (Columbus Ohio, U.S.A.) COUGHLIN ROBERT W. et al. "Simplified flow reactor for electrochemically driven enzymic reactions involving cofactors", see page 178, Abstract No. 189837f Biotechnol. Bioeng. 1975, 17 (9), 1379-82. *
CHEMICAL ABSTRACTS, Vol. 84, No. 17, issued April 26, 1976 (Columbus Ohio. U.S.A.) AIZAWA MASUO et al. "Electrolytic regeneration of the raduced from the oxidized form of immobilized NAD" see page 201, the Abstract No. 117673x Biotechnol. Bioeng. 1976, 18 (2), 209-15 (Eng). *
CHEMICAL ABSTRACTS, Vol. 84, No. 19, issued May 10, 1976, (Columbus Ohio, U.S.A.) GOCHEY A. "Electrochemical model of enzymatic redox reactions with an electron transfer limiting stage", see page 190, Abstract No. 131954w Biofizika 1976, 21 (1), 5-9 (Russ.). *
CHEMICAL ABSTRACTS, Vol. 88, No. 7, issued February 13, 1978 (Columbus Ohio, U.S.A.) S.D. VARFOLOMEEV et al. "Bioelectrocatalysis. Hydrogenase as catalyst of electrochemical hydrogan ionization" see page 214, the Abstract No. 46811k, Bioelectrochem. Bioenerg. 1977, 4 (3), 314-26 (Eng). *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981000725A1 (en) * 1979-09-14 1981-03-19 Charles Hospital Dev Method of determining a substrate in a sample
EP0030195A1 (en) * 1979-12-03 1981-06-10 Societe D'etudes De Techniques Et De Realisations Industrielles Et Commerciales (Setric) Method of measuring the concentration of an oxidisable or reducible substrate in solution by means of an oxido-reductase enzyme, and device for carrying out such a method
FR2470799A1 (en) * 1979-12-03 1981-06-12 Tech Realisa Indles Cales Et ELECTROCHEMICAL PROCESS FOR THE TRANSFORMATION OF AN OXIDIZABLE OR REDUCTIBLE SUBSTRATE BY MEANS OF AN OXYDO-REDUCTASE ENZYME AND APPLICATIONS TO CONCENTRATION MEASURES OR TO THE PRODUCTION OF AN OXIDIZED OR REDUCED FORM OF A SUBSTRATE AND DEVICES FOR IMPLEMENTING SUCH APPLICATIONS
EP0076266B1 (en) * 1981-04-08 1988-11-09 GORTON, Lo Electrode for the electrochemical regeneration of co-enzyme, a method of making said electrode, and the use thereof
WO1982004113A1 (en) * 1981-05-14 1982-11-25 Kylmaenen Pasi Feeding means for feeding solid fuel from a storage silo or equivalent into a solid fuel heating boiler
EP0068664A1 (en) * 1981-06-12 1983-01-05 Ajinomoto Co., Inc. A heme protein immobilized electrode
US4541908A (en) * 1981-06-12 1985-09-17 Ajinomoto Company Incorporated Heme protein immobilized electrode and its use
EP0099517A3 (en) * 1982-07-17 1985-10-16 Basf Aktiengesellschaft Process for carrying out electromicrobial reductions
EP0099517A2 (en) * 1982-07-17 1984-02-01 BASF Aktiengesellschaft Process for carrying out electromicrobial reductions
EP0125867A2 (en) * 1983-05-05 1984-11-21 MediSense, Inc. Assay systems using enzymes requiring NAD(P) as cofactor
EP0125867A3 (en) * 1983-05-05 1987-01-07 MediSense, Inc. Assay systems using enzymes requiring NAD(P) as cofactor
WO1988008029A1 (en) * 1987-04-17 1988-10-20 Centre National De La Recherche Scientifique (Cnrs Electroenzymatic method for producing compounds having a controlled enantiomeric purity
FR2614038A1 (en) * 1987-04-17 1988-10-21 Centre Nat Rech Scient ELECTROENZYMATIC PROCESS FOR THE PRODUCTION OF CONTROLLED ENANTIOMERIC PURE COMPOUNDS
US6126795A (en) * 1996-11-27 2000-10-03 The United States Of America As Represented By The Secretary Of Commerce Electroenzymatic reactor and method for enzymatic catalysis
US6306280B1 (en) 1996-11-27 2001-10-23 The United States Of America As Represented By The Secretary Of Commerce Electroenzymatic reactor and method for enzymatic catalysis
WO2011053478A1 (en) * 2009-10-26 2011-05-05 Saudi Arabian Oil Company Visible light-enhanced enzymatic promotion of hydrocarbon reactions

Also Published As

Publication number Publication date
DE2966707D1 (en) 1984-03-29
JPS55500431A (en) 1980-07-17
IT1165700B (en) 1987-04-22
EP0020355B1 (en) 1984-02-22
US4318784A (en) 1982-03-09
IT7968676A0 (en) 1979-08-16
EP0020355A1 (en) 1981-01-07

Similar Documents

Publication Publication Date Title
EP0020355B1 (en) Enzymatic processes
Amao Formate dehydrogenase for CO2 utilization and its application
Faulkner et al. Electrocatalytically driven omega-hydroxylation of fatty acids using cytochrome P450 4A1.
Buckel et al. Energy conservation via electron bifurcating ferredoxin reduction and proton/Na+ translocating ferredoxin oxidation
Park et al. Utilization of electrically reduced neutral red by Actinobacillus succinogenes: physiological function of neutral red in membrane-driven fumarate reduction and energy conservation
Im et al. Electrochemically enhanced microbial CO conversion to volatile fatty acids using neutral red as an electron mediator
US6306280B1 (en) Electroenzymatic reactor and method for enzymatic catalysis
Hill et al. Bioelectrocatalysis
Gärtner et al. Expression of Shewanella oneidensis MR-1 [FeFe]-hydrogenase genes in Anabaena sp. strain PCC 7120
Tarasevich Ways of using enzymes for acceration of electrochemical reactions
US20210171995A1 (en) Method for Using Electrochemical Bioreactor Module with Recovery of Cofactor
US6991926B2 (en) Method comprising the indirect electrochemical regeneration of NAD(P)H
FI76376C (en) Method for carrying out electromicrobial reductions
Brielbeck et al. Continuous electroenzymatic synthesis employing the electrochemical enzyme membrane reactor
Shin et al. Hydrogen production from formic acid in pH-stat fed-batch operation for direct supply to fuel cell
Hilt et al. Efficient In‐Situ Redox Catalytic NAD (P)+ Regeneration in Enzymatic Synthesis Using Transition‐Metal Complexes of 1, 10‐Phenanthroline‐5, 6‐dione and Its N‐Monomethylated Derivative as Catalysts
JP4092401B2 (en) Hydrogen production method
GB2033428A (en) Enzymatic Processes
Adlercreutz et al. Oxygen supply to immobilized cells: 4. Use of p-benzoquinone as an oxygen substitute
Kreysa et al. Macrokinetics and mathematical modelling of quinone reduction by cyanobacteria
Fontecave et al. Mechanisms of formation of free radicals in biological catalysis
Higgins et al. Electroenzymology and biofuel cells
CN113481264A (en) Method for preparing cofactor by coupling leucine dehydrogenase with photoelectrocatalysis
KR20020001519A (en) Electro-chemical Preparation of Acetic acid
JPS6371187A (en) Enzymatic oxidation method

Legal Events

Date Code Title Description
AK Designated states

Designated state(s): JP US

AL Designated countries for regional patents

Designated state(s): DE FR NL

AN Elected states

Free format text: JP